Compare Figs Inc (FIGS) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Figs Inc trades at $18.54 (market cap $2.99B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Figs Inc is far larger — about 3.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Figs Inc is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 31 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FIGS | MRVI | |
|---|---|---|
Market Cap | $2.99B | $972.90M |
Volume | 6,721,481 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.63 | $9.00 |
52-Week Low | $7.38 | $2.83 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $2.75B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $18.63, up 4.9% today, showing strong momentum with three consecutive quarterly earnings beats. The company demonstrates robust fundamentals with 68.9% gross margins and accelerating revenue growth from $556M in 2024 to projected $710M in 2026. Technical indicators show bullish momentum with the stock trading near resistance at $19, though RSI levels suggest potential overbought conditions. Recent news highlights international expansion success with 67% Q2 international sales growth and raised 2026 guidance.
The outlook remains positive with analyst consensus pointing to 26% upside potential to $18 target, though the premium valuation (P/E 54.6) requires continued execution. Key risks include rich valuation multiples and competitive pressures in healthcare apparel. The combination of strong earnings momentum, international growth, and bullish technicals supports further upside if the company maintains its growth trajectory.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
